RNAscope® technology is being routinely used for tissue-based gene expression analysis in biopharma for target validation, pathobiology and biomarker development in every disease area. This technology, with its capacity to provide single-cell and single-RNA molecule sensitivity in the context of complex tissue microenvironments, is an ideal tool to complement technologies like IHC, qPCR or NGS.

Our recent advances in RNAscope® technology, now enables detection of mRNA, mutations, and exon junctions. The presenters at this symposium will discuss how they have successfully applied RNA ISH to their research and will highlight the benefits of RNAscope® technology.

We would also like to extend this invitation to your colleagues and other scientists in your organization who are using molecular methods for disease characterization and are interested in new RNA analysis technologies. 




February 23, 2017 - 11:30 am to 3:00 pm

Lunch will be provided
Presidio Room, Embassy Suites South SF, 
250 Gateway Blvd, South San Francisco, CA 94080



  • Brief introduction of RNAscope® technology
    Vanee Pho, Ph.D,  Advanced Cell Diagnostics, Inc.

  • Therapeutic antibodies reveal Notch control of trans-differentiation in the adult lung
    Daniel Lafkas, Ph.D, Genentech, Inc.

  • Breakthrough RNA ISH assays for detection of mRNA, isoforms and sequence mutations in fixed animal and human tissues
    Chris Bunker, Ph.D, Advanced Cell Diagnostics, Inc.

  • Discussion session


For more information contact:
Li Fang